Analysts Expect Unum Therapeutics Inc (NASDAQ:UMRX) Will Announce Earnings of -$0.31 Per Share

Analysts expect Unum Therapeutics Inc (NASDAQ:UMRX) to report ($0.31) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Unum Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.41). Unum Therapeutics posted earnings of ($0.29) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 6.9%. The company is scheduled to issue its next quarterly earnings results on Thursday, March 26th.

On average, analysts expect that Unum Therapeutics will report full-year earnings of ($1.42) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.34). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.11) per share, with EPS estimates ranging from ($1.60) to ($0.73). Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Unum Therapeutics.

Unum Therapeutics (NASDAQ:UMRX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.07). Unum Therapeutics had a negative net margin of 388.07% and a negative return on equity of 96.07%. The firm had revenue of $1.02 million during the quarter, compared to analyst estimates of $4.41 million.

A number of research analysts have issued reports on the company. Wedbush decreased their target price on Unum Therapeutics from $20.00 to $13.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. They noted that the move was a valuation call. HC Wainwright reaffirmed a “buy” rating on shares of Unum Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley cut their price objective on Unum Therapeutics from $8.00 to $3.00 and set an “overweight” rating on the stock in a report on Wednesday, November 27th. Zacks Investment Research raised Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a research note on Saturday, November 9th. Finally, Cowen reaffirmed a “hold” rating on shares of Unum Therapeutics in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $8.30.

Several hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC grew its stake in shares of Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock worth $85,000 after acquiring an additional 18,717 shares in the last quarter. Tower Research Capital LLC TRC acquired a new position in Unum Therapeutics during the third quarter worth $31,000. Susquehanna International Group LLP acquired a new position in Unum Therapeutics during the second quarter worth $62,000. Wedbush Securities Inc. bought a new position in Unum Therapeutics in the third quarter valued at $48,000. Finally, Jane Street Group LLC bought a new position in Unum Therapeutics in the second quarter valued at $132,000. 43.02% of the stock is owned by institutional investors.

Unum Therapeutics stock traded down $0.02 during mid-day trading on Friday, hitting $0.67. 206,530 shares of the company’s stock were exchanged, compared to its average volume of 146,254. The company’s 50 day simple moving average is $1.10 and its 200-day simple moving average is $1.96. The company has a quick ratio of 1.96, a current ratio of 1.96 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $22.55 million, a P/E ratio of -0.48 and a beta of 1.01. Unum Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $6.74.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).

Read More: What Does a Sell-Side Analyst Rating Mean?

Get a free copy of the Zacks research report on Unum Therapeutics (UMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Unum Therapeutics (NASDAQ:UMRX)

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.